Recent Quotes (30 days)

You have no recent quotes
chg | %

Biosyent Inc.  

(Public, CVE:RX)   Watch this stock  
Find more results for RX
-0.16 (-1.74%)
Apr 1 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 8.66 - 9.30
52 week 4.72 - 12.82
Open 9.26
Vol / Avg. 53,861.00/32,588.00
Mkt cap 125.66M
P/E 41.20
Div/yield     -
EPS 0.22
Shares 13.87M
Beta 0.88
Inst. own     -
Feb 25, 2015
Q4 2014 Biosyent Inc Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 24.63% 25.83%
Operating margin 30.41% 33.56%
EBITD margin - 33.94%
Return on average assets 30.47% 37.69%
Return on average equity 38.90% 48.47%
CDP Score - -


Suite 520, 170 Attwell Dr
+1-905-2060013 (Phone)
+1-905-2061413 (Fax)

Website links


Biosyent Inc. (Biosyent) is a Canada-based pharmaceutical company. The Company provides products to healthcare professionals. Biosyent acquires or in-licences pharmaceutical products and markets products in Canada through its subsidiary, BioSyent Pharma Inc. The Company markets bio and health friendly non-chemical insecticides through its subsidiary, Hedley Technologies Ltd. The Company manufactures and markets a bio-friendly non-toxic product Protect-It. The Protect-It is a non-chemical, food-safe grain insecticide. The Protect-It is used as a preventative treatment against insect infestations. The Company launched FeraMAX 150, an oral hematinic to the Canadian healthcare market through its subsidiary. The FeraMAX 150 is indicated for the prevention and treatment of iron deficiency anaemia (IDA).

Officers and directors

Rene C. Goehrum Chairman of the Board, President, Chief Executive Officer
Alfred D'Souza Chief Financial Officer
Kevin Wilson Vice President - Sales and Marketing of BioSyent Pharma Inc
Douglas R. Larson Secretary, Director
Peter D. Lockhard Independent Director
Paul R. Montador Independent Director
Milton E. Wakefield Independent Director
Stephen Wilton Independent Director